CRYOPORT, INC. Deferred State and Local Income Tax Expense (Benefit)
CRYOPORT, INC. (CYRX) reported Deferred State and Local Income Tax Expense (Benefit) of $86.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-03-05
- CRYOPORT, INC. deferred state and local income tax expense (benefit) for fiscal 2025 was $86.00K.
- CRYOPORT, INC. deferred state and local income tax expense (benefit) for fiscal 2024 was -$126.00K.
- CRYOPORT, INC. deferred state and local income tax expense (benefit) for fiscal 2023 was -$423.00K.
- CRYOPORT, INC. deferred state and local income tax expense (benefit) for fiscal 2022 was -$191.00K.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month | Deferred State and Local Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $86.00K 10-K · filed 2026-03-05 | |
| 2024-12-31 | -$126.00K 10-K · filed 2026-03-05 | |
| 2023-12-31 | -$423.00K 10-K · filed 2026-03-05 | |
| 2022-12-31 | -$191.00K 10-K · filed 2025-03-07 | |
| 2021-12-31 | -$1.56M 10-K · filed 2024-03-13 | |
| 2020-12-31 | -$832.00K 10-K · filed 2023-02-28 | |
| 2019-12-31 | $5.00K 10-K · filed 2022-02-28 | |
| 2018-12-31 | -$399.00K 10-K · filed 2020-03-10 | $399.00K 10-K · filed 2019-03-13 |
| 2017-12-31 | -$320.00K 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |